Heartland Advisors Inc. Has $1.61 Million Stock Holdings in Perrigo Company plc $PRGO

Posted by Geri Gentry on Jul 20th, 2026

Heartland Advisors Inc. lowered its stake in Perrigo Company plc (NYSE:PRGO – Free Report) by 32.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,219 shares of the company’s stock after selling 73,764 shares during the period. Heartland Advisors Inc. owned 0.11% of Perrigo worth $1,613,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PRGO. EverSource Wealth Advisors LLC increased its holdings in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after acquiring an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Perrigo during the 4th quarter worth $28,000. Finally, CWM LLC grew its position in Perrigo by 230.0% during the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after acquiring an additional 1,527 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Trading Up 0.1%

Shares of PRGO stock opened at $10.73 on Monday. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $28.43. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -0.82, a PEG ratio of 1.27 and a beta of 0.51. The stock has a 50-day moving average of $10.66 and a 200-day moving average of $11.90.

Perrigo (NYSE:PRGO – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the firm earned $0.60 earnings per share. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities research analysts forecast that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were given a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.8%. Perrigo’s payout ratio is -8.85%.

Wall Street Analyst Weigh In

PRGO has been the subject of several research reports. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.33.

View Our Latest Report on PRGO

Perrigo Company Profile

(Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.